The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
March 24th 2023
Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab).
Retinal Physicians Report Reservations Around Ophthalmology BiosimilarsFebruary 20th 2023
There are 2 ranibizumab biosimilars approved in the United States, and with more ranibizumab and the first aflibercept biosimilars on the horizon, gaps in knowledge among retinal physicians should be addressed.
Humira: The First $20 Billion DrugFebruary 8th 2023
The authors review a House Oversight Committee investigation report on AbbVie’s practices pertaining to adalimumab (Humira) to shed light on broader pharmaceutical market dynamics hindering a competitive market.
First Humira Biosimilar, Amjevita, Launches in the United StatesJanuary 31st 2023
The first of at least 8 adalimumab biosimilars has finally launched in the United States after being kept off the market for years due to settlement agreements with the maker of the reference product, Humira.
PBMs Announce 2023 Coverage Plans for Adalimumab BiosimilarsJanuary 1st 2023
The addition of adalimumab biosimilars to formularies can help accelerate realized savings as the blockbuster drug Humira faces competition from multiple biosimilars, including 1 approved interchangeable biosimilar.
Tocilizumab Biosimilars Show Similar Safety, Tolerability, Immunogenicity to Reference: ACR AbstractsDecember 14th 2022
Abstracts presented at the annual meeting of the American College of Rheumatology (ACR) show 2 tocilizumab biosimilars were comparable to the reference product.
Oncologists’ Perceptions and Utilization of US Therapeutic Oncology Biosimilars
Biosimilar use in clinical practice is determined by oncologists’ perceptions of and willingness to prescribe them. The authors investigated US oncologists’ perceptions and use of biosimilars.
US Biosimilars Substantially More Expensive Than Those in Germany, SwitzerlandDecember 5th 2022
Due to anticompetitive practices, the United States lags Germany and Switzerland in the number of biosimilars on the market, while also having substantially higher prices for both biosimilars and reference products.
Driving Biosimilar Uptake in Rheumatology, Biosimilar-to-Biosimilar Switching: ACR AbstractsNovember 26th 2022
Abstracts show that institutions can make internal changes to drive the use of biosimilars and that successful biosimilar-to-biosimilar switching is based on patient-related factors.
The Price Paradox of Biosimilar-Like Long-Acting Insulin
Findings suggest that Basaglar was not less expensive for patients than Lantus. Empirical evaluation of biosimilar costs prior to automatic substitution is necessary.
Rheumatologists Grow More Comfortable With Biosimilars, but Concerns RemainNovember 4th 2022
Ahead of the big wave of adalimumab biosimilars launching in the US market in 2023, rheumatologists report growing confidence in using biosimilars but remain concerned about their efficacy and economic benefit.
Multidisciplinary Care as the Catalyst for Innovation in OncologyOctober 21st 2022
Coverage from the Atlanta meeting of the Institute for Value-Based Medicine, chaired by Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services, Emory Healthcare and Emory Winship Cancer Institute.
Medicare Part B Pricing Changes Aimed at Encouraging Biosimilar Use BeginOctober 3rd 2022
One of the first parts of the landmark Inflation Reduction Act took effect Monday; it boosts the add-on payment for qualifying biosimilars whose average sales price is not more than the price of its reference product from 6% of the reference product’s ASP to 8% for 5 years.
Multiple Pegfilgrastim Administration Options Allow for Patient-Centric Model of CareSeptember 20th 2022
With 6 pegfilgrastim biosimilars approved, and multiple administration options, a patient-centric model of pegfilgrastim administration should be possible for patients with cancer who require prophylaxis of febrile neutropenia.
Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast CancerSeptember 14th 2022
The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2)–positive early-stage (neoadjuvant and adjuvant therapy) and metastatic (palliative therapy) breast cancer using real-world data.
Practices Have to Grapple With the Logistics of Insurers’ Preferred Biosimilars: Dr Lalan WilfongSeptember 11th 2022
While commercial payers have been engaged with the shift to biosimilars, they all have their own preferred biosimilar, which makes it challenging for practices, explained Lalan Wilfong, MD, vice president of payer relations & practice transformation at The US Oncology Network.